PCN5 BUDGET IMPACT ANALYSIS OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. ORAL IBANDRONATE OR IV GENERIC PAMIDRONATE IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES- A UK NHS PERSPECTIVE
Abstract
Authors
M Botteman M Aapro J Stephens JW Hay J Brandman